Quantitative Disease Progression Model of Alpha-1 Proteinase Inhibitor Therapy on CT Lung Density in Patients with Alpha-1 Antitrypsin Deficiency.

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. Nucleic Acids Res (2015) 10.66

The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol (2015) 5.96

American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med (2003) 3.59

Augmentation therapy for alpha1 antitrypsin deficiency: a meta-analysis. COPD (2009) 2.41

A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med (1999) 1.99

Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet (2015) 1.87

A review of α1-antitrypsin deficiency. Am J Respir Crit Care Med (2011) 1.57

Pharmacokinetic study of alpha1-antitrypsin infusion in alpha1-antitrypsin deficiency. Chest (1997) 1.54

Use of a highly purified alpha 1-antitrypsin standard to establish ranges for the common normal and deficient alpha 1-antitrypsin phenotypes. Chest (1991) 1.51

Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J (2009) 1.41

Biochemical efficacy and safety of monthly augmentation therapy for alpha 1-antitrypsin deficiency. JAMA (1988) 1.29

Validation of computed tomographic lung densitometry for monitoring emphysema in alpha1-antitrypsin deficiency. Thorax (2006) 1.24

Serum levels and genotype distribution of α1-antitrypsin in the general population. Thorax (2012) 0.98

Alpha-1-antitrypsin deficiency: optimal therapeutic regimen based on population pharmacokinetics. Thorax (2006) 0.89

Augmentation therapy in alpha-1 antitrypsin deficiency: advances and controversies. Ther Adv Respir Dis (2010) 0.86

Safety and pharmacokinetics of 120 mg/kg versus 60 mg/kg weekly intravenous infusions of alpha-1 proteinase inhibitor in alpha-1 antitrypsin deficiency: a multicenter, randomized, double-blind, crossover study (SPARK). COPD (2013) 0.79

Multi-center study: the biochemical efficacy, safety and tolerability of a new alpha1-proteinase inhibitor, Zemaira. COPD (2006) 0.78

Lung density associates with survival in alpha 1 antitrypsin deficient patients. Respir Med (2016) 0.78

Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir Med (2016) 0.77

How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency? PLoS One (2015) 0.80

Does urinary peptide content differ between COPD patients with and without inherited alpha-1 antitrypsin deficiency? Int J Chron Obstruct Pulmon Dis (2017) 0.75

Alpha1-antitrypsin binds hemin and prevents oxidative activation of human neutrophils: putative pathophysiological significance. J Leukoc Biol (2017) 0.75